<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006372</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU1Y99</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CWRU-1Y99</secondary_id>
    <secondary_id>NCI-G00-1859</secondary_id>
    <nct_id>NCT00006372</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Trial of Combination Pegylated Liposomal Doxorubicin (Doxil), Vinorelbine, and Gemcitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating&#xD;
      patients who have advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of gemcitabine, doxorubicin HCl liposome, and&#xD;
           vinorelbine in patients with advanced solid tumors.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of this regimen in these patients.&#xD;
&#xD;
        -  Determine the toxicity profile of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1, gemcitabine IV over&#xD;
      30 minutes on days 1 and 8, and vinorelbine IV over 6-10 minutes on days 1 and 15. Treatment&#xD;
      continues every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome, gemcitabine,&#xD;
      and vinorelbine until the maximum tolerated dose (MTD) is determined. The MTD is defined as&#xD;
      the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for up to 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 9-24 patients will be accrued for this study within 12-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">10</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin hydrochloride</intervention_name>
    <description>Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine ditartrate</intervention_name>
    <description>Patients receive vinorelbine IV over 6-10 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor not amenable to curative surgery, radiotherapy,&#xD;
             or chemotherapy&#xD;
&#xD;
          -  No brain metastases or primary brain tumors&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin greater than 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.2 mg/dL&#xD;
&#xD;
          -  AST and/or ALT less than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  PT no greater than ULN (anticoagulant independent)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL AND/OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  LVEF at least 45% by MUGA or echocardiogram&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior bone marrow or peripheral blood stem cell transplantation following high dose&#xD;
             chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior biologic therapy for cancer and recovered&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen&#xD;
&#xD;
          -  No prior vinca alkaloids&#xD;
&#xD;
          -  Prior anthracycline allowed if total dose no greater than 300 mg/m2&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or carmustine) and&#xD;
             recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior endocrine therapy for cancer and recovered&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 1 prior radiotherapy regimen&#xD;
&#xD;
          -  At least 4 weeks since prior large field radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy for cancer and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth A. Overmoyer, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>October 4, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Beth A. Overmoyer, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

